RecruitingNCT06439303
Analysis and Evaluation of Smoking Treatment With Cytisine
Analysis and Evaluation of Smoking Treatment With Cytisine: Retrospective Observational Study
Sponsor
Regina Elena Cancer Institute
Enrollment
65 participants
Start Date
Mar 20, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- patients aged \> 18 years;
- patients suffering from moderate or severe tobacco use disorder;
- prescription of pharmacological therapy with Cytisine;
- patients returned to the 1st check-up on schedule;
Exclusion Criteria4
- Patients with contraindications to taking Cytisine and partial receptor agonists nicotinic cholinergics;
- Patients undergoing pharmacological or physical treatment for neoplastic pathology;
- Pregnant or breastfeeding women;
- Patients for whom specific information for objective assessments is not available;
Interventions
DRUGCytisine 1,5 mg
Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06439303